| Product Name | Lapaquistat acetate (Synonyms: TAK-475) | 
|---|---|
| CAS | 189060-13-7 | 
| Formula | C33H41ClN2O9 | 
| MW | 645.14 | 
| MDL | MFCD06407873 | 
| Appearance | White to off-white powder | 
| Storage condition | Store short-term at 0-4°C or long-term at -20°C in a dry, dark place. | 
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity | 
|---|---|---|---|---|
| 1 mg | 3-5 days | ¥1488.00 | Visible after login | |
| 2 mg | 3-5 days | ¥2266.00 | Visible after login | |
| 5 mg | 3-5 days | ¥3626.00 | Visible after login | 
| Product Name | Lapaquistat acetate (Synonyms: TAK-475) | 
|---|---|
| CAS | 189060-13-7 | 
| Formula | C33H41ClN2O9 | 
| MW | 645.14 | 
| MDL | MFCD06407873 | 
| Appearance | White to off-white powder | 
| Storage condition | Store short-term at 0-4°C or long-term at -20°C in a dry, dark place. | 
Lapaquistat acetate, a potent squalene synthase inhibitor, impedes the conversion of farnesyl diphosphate (FPP) to squalene, a key step in cholesterol synthesis. Utilized in treating Mevalonate Kinase Deficiency (MKD), an autosomal recessive disorder, it significantly reduces low-density lipoprotein cholesterol levels. However, its use may be accompanied by liver damage, a known side effect that warrants monitoring.
Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice
PMID: 28901277 DOI: 10.2174/0929867324666170911161417
Br J Pharmacol. 2008 Jul;154(5):949-57.
PMID: 21518985 DOI: 10.1161/CIRCULATIONAHA.110.975284